Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
- Sales of 10 Top European, US Drug Makers See Sharp Declines in 2012 Due to Patent Cliff
February 13, 2013
- Naglazyme Sales and Development Funds Grow for AnGes MG in April-December
February 12, 2013
- Eli Lilly to Discontinue Development of Tabalumab for RA
February 12, 2013
- Will Lotriga Create a New Market or Battle Head to Head with Epadel?
February 12, 2013
- Ethical Drug Sales Down 2.5% in December: Crecon Report
February 8, 2013
- Seikagaku to Initiate PII Trial in Japan of Knee Osteoarthritis Treatment
February 8, 2013
- Chugai Applies for Once-Weekly Herceptin for Postoperative Adjuvant Chemotherapy in Breast Cancer Based on Data from Public Domain
February 8, 2013
- Asahi Kasei Pharma Reports Strong Growth for April-December 2012; Sales of Teribone Break 12 Billion Yen Mark
February 8, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- DSP President Expects Launch of PMDA-WEST, Says Kansai Firms Are at Disadvantage
February 7, 2013
- EMA Approves Otsuka’s Abilify for the Treatment of Manic Episodes in Bipolar I Disorder in Adolescents
February 7, 2013
- 4 Major Wholesalers’ Price Settlement Rates Lower than 2 Years Ago, Negotiations Charging into Final Phase: April-Dec. Earnings
February 7, 2013
- Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
- Sales and Profits Jump for Shionogi in April-December with US Sales Recovery
February 6, 2013
- Latuda Serves as Driving Force for Growth in North American Market: DSP President Tada
February 6, 2013
- Takeda Lowers Full-Year Sales Forecast for Nesina, but Says Nesina Remains “Fastest-Growing DPP-4 Inhibitor”
February 6, 2013
- Sales in Emerging Markets Contribute to Growth in Sales for April-December Despite Fall in Sales of All 4 Major Products: Takeda
February 6, 2013
- Daiichi Sankyo Starts PIII Trial of ARQ 197 in HCC Patients
February 5, 2013
- DSP Posts 46.5 % Rise in April-December Operating Profit Despite Japan Sales Fall
February 5, 2013
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…